ArticleOncology letters2026
Efficacy of induction chemotherapy combined with standard chemoradiotherapy vs. standard chemoradiotherapy monotherapy in locally advanced cervical cancer: A systematic review and meta-analysis.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer (LACC); however, the role of additional induction chemotherapy (IC) remains debated. The present study performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to comparatively assess therapeutic outcomes and safety profiles between induction chemotherapy followed by concurrent chemoradiotherapy (IC + CCRT) versus CCRT alone in patients with locally advanced cervical cancer (LACC) (International Federation of Gynecology and Obstetrics 2018 stage IB2-IVA). The study screened relevant literature published up to March 2025 and ultimately included 6 RCTs, where 1,006 patients were stratified (504 in the IC + CCRT regimen vs. 502 in the CCRT alone regimen). Compared with CCRT alone, IC + CCRT significantly improved the complete response (CR) rate [odds ratio (OR), 1.95; 95% confidence interval (CI), 1.20-3.17; P=0.007] and 1-year progression-free survival rate (OR, 1.82; 95% CI, 1.14-2.90; P=0.01). A consistent trend favoring IC+CCRT was observed for overall survival, although this was not statistically significant. Hematological toxicities, notably thrombocytopenia (OR, 1.76; 95% CI, 1.06-2.90; P=0.03) and neutropenia (OR, 2.69; 95% CI, 1.09-6.61; P=0.03), were more frequent with IC+CCRT, while non-hematological toxicity profiles were comparable. In conclusion, the addition of modern, short-course induction chemotherapy to CCRT enhances the CR rate and 1-year progression-free survival rate in LACC, establishing a promising intensified treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.